Friday August 21, 2026

2026 Interim Results Investor Call

Dear Investors:

Hua Medicine (2552.HK) cordially invites you or your representative to attend the conference call for the Company's 2026 interim results, which will be held 11:30 AM HKT, August 21, 2026 (Friday).

During the conference call, management will provide a review of the Company's 2026 interim results, business updates, as well as address plans for its future.

Details of the earnings call are as follows:

Date:	August 21, 2026
Time:	Login starts: 11:15AM HKT Meeting starts: 11:30AM
Duration:	Approximately 60 minutes (including Q&A session)
Language:	English
Management:	Dr. Li Chen, Founder and CEO George Lin, EVP & Chief Strategy Officer
Moderator :	Matthew Yan, CLSA Research Analyst
RSVP:	Please register in advance via this link: https://clsa.zoom.com/webinar/register/WN_ULc3ijqXTKubPUmU40DFUA After registration, you will receive a confirmation email containing details about joining the zoom meeting

About Hua Medicine

Hua Medicine (the "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in patients with Type 2 diabetes (T2D), and stabilizes imbalances in blood glucose levels in patients. HuaTangNing (华堂宁®) was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin for adult patients with Type 2 diabetes. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral glucose lowering drug that can be used in T2D patients with renal function impairment.

In February 2026, dorzagliatin (trade name: MYHOMSIS®, 華領片®) was approved for marketing by the Pharmaceutical Service of the Department of Health of the Government of the Hong Kong Special Administrative Region of the People's Republic of China. In June 2026, dorzagliatin (trade name: MYHOMSIS®, 華領片®) was approved for marketing by the Pharmaceutical Administration Bureau of Macao Special Administrative Region of the People's Republic of China.